Equities research analysts at Laidlaw initiated coverage on shares of Senti Biosciences (NASDAQ:SNTI - Get Free Report) in a research report issued on Friday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. Laidlaw's price target points to a potential upside of 60.26% from the company's previous close.
Separately, Chardan Capital restated a "buy" rating and set a $12.00 price objective on shares of Senti Biosciences in a report on Friday, May 2nd.
Read Our Latest Stock Report on SNTI
Senti Biosciences Price Performance
Shares of Senti Biosciences stock traded down $0.72 during trading on Friday, reaching $3.12. 287,738 shares of the company traded hands, compared to its average volume of 804,275. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50 day moving average price of $3.39 and a 200-day moving average price of $3.84. The firm has a market capitalization of $81.37 million, a PE ratio of -0.20 and a beta of 2.23.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The business had revenue of $1.30 million for the quarter, compared to analysts' expectations of $1.30 million. Equities research analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.
Institutional Trading of Senti Biosciences
Several institutional investors have recently made changes to their positions in SNTI. Virtu Financial LLC bought a new stake in shares of Senti Biosciences in the 4th quarter worth $47,000. Renaissance Technologies LLC bought a new stake in shares of Senti Biosciences in the 4th quarter worth $181,000. Heights Capital Management Inc. bought a new stake in shares of Senti Biosciences in the 1st quarter worth $2,520,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Senti Biosciences in the 1st quarter worth $2,984,000. Institutional investors own 25.73% of the company's stock.
About Senti Biosciences
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Further Reading
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
